Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.

Further, with approximately one-third of U.S. adults suffering from obesity, we believe the company’s GLP[1]1 drug has the potential to address a large market once approved.” Overall ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

naming obesity drug developer Viking Therapeutics (NASDAQ:VKTX) in the list. "The second week of January tends to be a bellwether for biotech M&A and a broader gauge of sector sentiment," analyst ...

Blockbuster obesity drugs such as Ozempic have been celebrated for their ability to promote weight loss and treat a surprising range of other conditions, from heart problems to Parkinson’s disease.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

LLY stock fell nearly 7% after this announcement. Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro ...